. 2018 May 24;3(1):2381468318776634. doi: 10.1177/2381468318776634

Table 10.

Estimated Time to Achieve a 90% Reduction in HCV Prevalence Among PWID Given the Community Prevalence, Access to Harm Reduction Programs, and Access to HCV Treatment

Reference	Country/City	Prevalence of HCV in PWID	Level of Harm Reduction Effort	90% Prevalence Decline Achieved by	Treatment Level Required (Annual)
Reference	Country/City	Prevalence of HCV in PWID	Level of Harm Reduction Effort	90% Prevalence Decline Achieved by	Rate per 1,000 PWID	% of HCV-Infected PWID^a
Bennett, 2015⁸⁷	Edinburgh, UK	25%	57% OST	15 years	40	16%
Fraser, 2017⁸⁵	US	55.3%	40% NSP	10 years	213	34.1%
Fraser, 2017⁸⁵	US	55.3%	50% NSP and OST	10 years	121	20%
Fraser, 2017⁸⁵	US	55.3%	40% NSP	15 years	159	25%
Fraser, 2017⁸⁵	US	55.3%	50% NSP and OST	15 years	89	14.5%
Gountas, 2017⁸⁴	Greece	64%	44% OST or NSP	10 years	258	40%
Gountas, 2017⁸⁴	Greece	64%	44% OST or NSP	15 years	125	19.5%

OST, opioid substitution therapy; NSP, needle-syringe exchange program.

^a.

In most cases this is estimated from the treatment rate per 1,000 PWID using the current prevalence rate and so it represents the fraction of HCV-positive PWID who would be treated in the first year.